Vaxtex Cotfab Limited Announces 21st AGM on Sep 30, 2026, to Appoint New Director
Vaxtex Cotfab Limited will hold its 21st AGM on September 30, 2026, via VC/OVAM. Key agenda items include adopting FY26 audited financials and appointing Mrs. Ansuiya Pareek as an Independent Director for five years from September 5, 2026. The meeting will also address the reversal of resolutions from the February 27, 2026 EOGM.
The appointment of a new independent director and the reversal of past resolutions are significant corporate actions that could impact governance and future strategic decisions. The AGM itself is a material event for shareholders.
The announcement is a routine corporate event (AGM) and includes standard agenda items like financial statement adoption and director appointment. The reversal of previous resolutions is a procedural matter and does not inherently indicate positive or negative performance.
Vaxtex Cotfab Limited has announced its 21st Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 02:00 P.M. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OVAM).
The AGM will transact ordinary business, including the consideration and adoption of the Audited Financial Statements for the Financial Year ended March 31, 2026, along with the Reports of the Board of Directors and Auditors.
In special business, the company will seek approval for the appointment of Mrs. Ansuiya Pareek (DIN: 10120917) as a Woman Non-Executive - Independent Director. Her appointment is proposed for a term of five years, from September 05, 2026, to September 04, 2031.
Additionally, the members will consider and pass a special resolution to reverse resolutions previously passed at the Extraordinary General Meeting (EOGM) held on February 27, 2026. This includes the reversal of Resolution No. 1 concerning the increase in the Authorized Share Capital of the Company.
What to do with a filing like this
Vaxtex Cotfab Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vaxtex Cotfab Limited. Read the original for the full detail.